Value of Ezrin, Maspin and Nm23-H1 Protein Expressions in Predicting Outcome of Patients with Head and Neck Squamous-cell Carcinoma Treated with Radical Radiotherapy

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2006 May 16

PMID 16698950

Citations 11

Authors

Paulette Mhawech-Fauceglia

Pavel Dulguerov

Amy Beck

Marta Bonet

Abdelkarim S Allal

Affiliations

Soon will be listed here.

Abstract

Background: Prognostic factors in predicting outcomes in patients with head and neck squamous-cell carcinoma (HNSCC) are limited to the clinical-pathological parameters, including lymph node metastasis, location, grade and stage of the disease.

Aim: To determine whether the expression of these proteins has a value in predicting patient outcome.

Methods: Ezrin, maspin and nm23-H1 immunohistochemistry in tissue samples of 120 patients with HNSCC were evaluated using the microarray technique.

Results: In determining the association among each of the three proteins and the clinical-pathological parameters, low maspin expression was the only one found to be significantly associated with high tumour grade (p = 0.007); all others showed no significant associations. In univariate analysis, patients with tumours expressing high ezrin had a shorter disease-free survival (DFS) of 51% than those with low ezrin expression (DFS 84%; p = 0.08). In multivariate analysis, tumours with the combination of loss of maspin and low histological grade had longer DFS (83%) compared with those with high maspin and high histological grade (DFS 42%; p = 0.08).

Conclusion: Our study is the first to determine the value of ezrin and maspin in HNSCC in a large series of patients with long follow-up. Ezrin and maspin seem to have a potential prognostic value in patients with HNSCC but results should be confirmed with further studies.

Citing Articles

Podoplanin, ezrin, and Rho-A proteins may have joint participation in tumor invasion of lip cancer.

Assao A, Nonogaki S, Lauris J, Carvalho A, Pinto C, Soares F Clin Oral Investig. 2016; 21(5):1647-1657.

PMID: 27628318 DOI: 10.1007/s00784-016-1956-3.

Prognostic Value of Ezrin in Various Cancers: A Systematic Review and Updated Meta-analysis.

Li J, Wei K, Yu H, Jin D, Wang G, Yu B Sci Rep. 2015; 5:17903.

PMID: 26632332 PMC: 4668575. DOI: 10.1038/srep17903.

A five-variable signature predicts radioresistance and prognosis in nasopharyngeal carcinoma patients receiving radical radiotherapy.

Yi H, Yi H, Zhu J, Xiao T, Lu S, Guan Y Tumour Biol. 2015; 37(3):2941-9.

PMID: 26409455 DOI: 10.1007/s13277-015-4139-y.

Are podoplanin and ezrin involved in the invasion process of the ameloblastomas?.

Costa Y, Tjioe K, Nonogaki S, Soares F, Lauris J, Oliveira D Eur J Histochem. 2015; 59(1):2451.

PMID: 25820557 PMC: 4378211. DOI: 10.4081/ejh.2015.2451.

The relationship between ezrin and podoplanin expressions in keratocystic odontogenic tumors.

Oliveira D, Santis L, Assao A, Tjioe K, Nonogaki S, Lauris J BMC Oral Health. 2014; 14:150.

PMID: 25480364 PMC: 4271494. DOI: 10.1186/1472-6831-14-150.

References

Pera E, Moreno A, Galindo L . Prognostic factors in laryngeal carcinoma. A multifactorial study of 416 cases. Cancer. 1986; 58(4):928-34. DOI: 10.1002/1097-0142(19860815)58:4<928::aid-cncr2820580421>3.0.co;2-j. View

Allal A, Dulguerov P, Bieri S, Lehmann W, Kurtz J . A conservation approach to pharyngeal carcinoma with advanced neck disease: optimizing neck management. Head Neck. 1999; 21(3):217-22. DOI: 10.1002/(sici)1097-0347(199905)21:3<217::aid-hed6>3.0.co;2-s. View

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View

Hanna E, Shrieve D, Ratanatharathorn V, Xia X, Breau R, Suen J . A novel alternative approach for prediction of radiation response of squamous cell carcinoma of head and neck. Cancer Res. 2001; 61(6):2376-80. View

Gunduz M, Ayhan A, Gullu I, Onerci M, Hosal A, Gursel B . nm23 Protein expression in larynx cancer and the relationship with metastasis. Eur J Cancer. 1998; 33(14):2338-41. DOI: 10.1016/s0959-8049(97)00321-3. View

Wang L, Chow K, Lien Y, Kuo K, Li W . Prognostic significance of nm23-H1 expression in esophageal squamous cell carcinoma. Eur J Cardiothorac Surg. 2004; 26(2):419-24. DOI: 10.1016/j.ejcts.2004.03.045. View

Mohsin S, Zhang M, Clark G, Allred D . Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol. 2003; 199(4):432-5. DOI: 10.1002/path.1319. View

Pavelic K, Kapitanovic S, Radosevic S, Bura M, Seiwerth S, Pavelic L . Increased activity of nm23-H1 gene in squamous cell carcinoma of the head and neck is associated with advanced disease and poor prognosis. J Mol Med (Berl). 2000; 78(2):111-8. DOI: 10.1007/s001090000081. View

Wang Y, Chow K, Chang S, Chiu J, Tai S, Li W . Prognostic significance of nm23-H1 expression in oral squamous cell carcinoma. Br J Cancer. 2004; 90(11):2186-93. PMC: 2409489. DOI: 10.1038/sj.bjc.6601808. View

10.

Moilanen J, Lassus H, Leminen A, Vaheri A, Butzow R, Carpen O . Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol. 2003; 90(2):273-81. DOI: 10.1016/s0090-8258(03)00262-2. View

11.

Ilmonen S, Vaheri A, Asko-Seljavaara S, Carpen O . Ezrin in primary cutaneous melanoma. Mod Pathol. 2004; 18(4):503-10. DOI: 10.1038/modpathol.3800300. View

12.

Maass N, Hojo T, Ueding M, Luttges J, Kloppel G, Jonat W . Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res. 2001; 7(4):812-7. View

13.

Landis S, Murray T, Bolden S, Wingo P . Cancer statistics, 1999. CA Cancer J Clin. 1999; 49(1):8-31, 1. DOI: 10.3322/canjclin.49.1.8. View

14.

Ngamkitidechakul C, Warejcka D, Burke J, OBrien W, Twining S . Sufficiency of the reactive site loop of maspin for induction of cell-matrix adhesion and inhibition of cell invasion. Conversion of ovalbumin to a maspin-like molecule. J Biol Chem. 2003; 278(34):31796-806. DOI: 10.1074/jbc.M302408200. View

15.

Elliott B, Meens J, SenGupta S, Louvard D, Arpin M . The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res. 2005; 7(3):R365-73. PMC: 1143558. DOI: 10.1186/bcr1006. View

16.

Crissman J, Liu W, Gluckman J, Cummings G . Prognostic value of histopathologic parameters in squamous cell carcinoma of the oropharynx. Cancer. 1984; 54(12):2995-3001. DOI: 10.1002/1097-0142(19841215)54:12<2995::aid-cncr2820541230>3.0.co;2-r. View

17.

Yasumatsu R, Nakashima T, Hirakawa N, Kumamoto Y, Kuratomi Y, Tomita K . Maspin expression in stage I and II oral tongue squamous cell carcinoma. Head Neck. 2002; 23(11):962-6. DOI: 10.1002/hed.1139. View

18.

WIERNIK G, Millard P, Haybittle J . The predictive value of histological classification into degrees of differentiation of squamous cell carcinoma of the larynx and hypopharynx compared with the survival of patients. Histopathology. 1991; 19(5):411-7. DOI: 10.1111/j.1365-2559.1991.tb00230.x. View

19.

Belbin T, Singh B, Smith R, Socci N, Wreesmann V, Sanchez-Carbayo M . Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2005; 131(1):10-8. DOI: 10.1001/archotol.131.1.10. View

20.

Weng W, Ahlen J, Astrom K, Lui W, Larsson C . Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res. 2005; 11(17):6198-204. DOI: 10.1158/1078-0432.CCR-05-0548. View